Citigroup Reiterates Positive Rating on BioPharma
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup reiterated a positive rating on shares of BioPharma. This rating was issued in a research report on Tuesday, September 22nd, according to one report. The company is publicly traded on the Nasdaq stock exchange.
From themarketsdaily.com
Why it matters
Investment ratings from Citigroup influence market perception of BioPharma. The stock currently has a consensus rating of “Hold” and an average target price of $14.50.
From themarketsdaily.com
Who's involved
Keep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
BioPharma
company in Jílové u Prahy, Czech Republic
Related events
- Citigroup provided a stock rating for Altimmune, Inc.
- Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.
- Citigroup involved in global financial markets; India and Canada aiming to close CEPA trade pact; Biocon arm seeks EMA CHMP approval for drug.
- Citigroup raised shares to a buy rating for Fisher & Paykel Healthcare.
- Citigroup reaffirmed a neutral rating and Morgan Stanley reiterated an overweight rating on Siemens Energy AG, which is headquartered in Germany.